EP3411079A4 - Cellules mammifères génétiquement modifiées pour thérapie anticancéreuse - Google Patents
Cellules mammifères génétiquement modifiées pour thérapie anticancéreuse Download PDFInfo
- Publication number
- EP3411079A4 EP3411079A4 EP17746953.3A EP17746953A EP3411079A4 EP 3411079 A4 EP3411079 A4 EP 3411079A4 EP 17746953 A EP17746953 A EP 17746953A EP 3411079 A4 EP3411079 A4 EP 3411079A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- mammalian cells
- cancer therapy
- engineered mammalian
- engineered
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004962 mammalian cell Anatomy 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4633—Antibodies or T cell engagers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016073489 | 2016-02-04 | ||
PCT/CN2016/087855 WO2017133175A1 (fr) | 2016-02-04 | 2016-06-30 | Cellules mammifères génétiquement modifiées pour thérapie anticancéreuse |
PCT/CN2017/072723 WO2017133633A1 (fr) | 2016-02-04 | 2017-01-26 | Cellules mammifères génétiquement modifiées pour thérapie anticancéreuse |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3411079A1 EP3411079A1 (fr) | 2018-12-12 |
EP3411079A4 true EP3411079A4 (fr) | 2019-10-30 |
Family
ID=59499323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17746953.3A Withdrawn EP3411079A4 (fr) | 2016-02-04 | 2017-01-26 | Cellules mammifères génétiquement modifiées pour thérapie anticancéreuse |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190038671A1 (fr) |
EP (1) | EP3411079A4 (fr) |
JP (1) | JP2019504892A (fr) |
CN (1) | CN108883202A (fr) |
WO (2) | WO2017133175A1 (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
CA2974651A1 (fr) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Polytherapie anticancereuse a base de smc |
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
US11185586B2 (en) | 2016-11-22 | 2021-11-30 | Alloplex Biotherapeutics, Inc. | Allogeneic tumor cell vaccine |
WO2018152572A1 (fr) * | 2017-02-21 | 2018-08-30 | The University Of Adelaide | Lymphocytes t exprimant des récepteurs de chimiokines pour le traitement du cancer |
WO2018191619A1 (fr) | 2017-04-13 | 2018-10-18 | Senti Biosciences, Inc. | Immunothérapie anticancéreuse combinatoire |
JP2020517263A (ja) * | 2017-04-19 | 2020-06-18 | ユニバーシティ オブ サザン カリフォルニア | がんを治療するための組成物及び方法 |
WO2019000223A1 (fr) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | Activateurs de cellules effectrices immunitaires d'anticorps chimériques et leurs procédés d'utilisation |
WO2019025800A1 (fr) * | 2017-08-02 | 2019-02-07 | Autolus Limited | Cellules exprimant un récepteur antigénique chimérique ou un tcr manipulé et comprenant une séquence de nucléotides exprimée de manière sélective |
GB201713078D0 (en) * | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
JP2020532987A (ja) * | 2017-09-08 | 2020-11-19 | ポセイダ セラピューティクス,インコーポレイティド | キメラリガンド受容体(clr)介在性の条件遺伝子発現のための組成物および方法 |
WO2019077037A1 (fr) * | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Procédés et composés pour une thérapie par cellules immunitaires améliorées |
CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
EP4279501A3 (fr) * | 2018-02-15 | 2024-02-28 | The National Institute for Biotechnology in the Negev Ltd. | Expression de recepteurs chimeriques d'antigenes specifique a un environnement tumoral |
WO2019177011A1 (fr) * | 2018-03-13 | 2019-09-19 | 国立大学法人大阪大学 | Immunostimulateur de tumeur |
AU2019253562A1 (en) * | 2018-04-09 | 2020-11-19 | The Trustees Of The University Of Pennsylvania | Methods and compositions comprising a viral vector for expression of a transgene and an effector |
CN110615842B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含共刺激受体的嵌合抗原受体及应用 |
CN108913718A (zh) * | 2018-07-20 | 2018-11-30 | 苏州茂行生物科技有限公司 | 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用 |
CN108949825A (zh) * | 2018-07-30 | 2018-12-07 | 苏州茂行生物科技有限公司 | 一种靶向her2的car-t细胞的制备方法及应用 |
US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
JP2022500022A (ja) * | 2018-09-05 | 2022-01-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | T細胞改変 |
CN113164518A (zh) | 2018-10-17 | 2021-07-23 | 森迪生物科学公司 | 组合癌症免疫疗法 |
US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
EP3876977A1 (fr) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Récepteurs antigéniques chimériques pour la phagocytose |
CN113226335B (zh) * | 2018-12-06 | 2023-10-13 | 广东天科雅生物医药科技有限公司 | 靶向肿瘤抗原、TGF-β、和免疫检查点的组合型TCR-T细胞疗法 |
US20220088075A1 (en) * | 2019-02-22 | 2022-03-24 | The Trustees Of The University Of Pennsylvania | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
US20220175833A1 (en) * | 2019-03-07 | 2022-06-09 | Children's Medical Center Corporation | Targeted delivery of immune-modulating vhh and vhh-fusion protein |
WO2020219504A1 (fr) * | 2019-04-23 | 2020-10-29 | The Regents Of The University Of California | Modulation de la survie de cellules thérapeutiques et procédés, cellules et acides nucléiques associés à celles-ci |
US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
WO2021016598A1 (fr) * | 2019-07-25 | 2021-01-28 | Immunowake Inc. | Méthodes de mesure de la mort à médiation cellulaire par des effecteurs |
BR112022001407A2 (pt) * | 2019-08-01 | 2022-05-03 | Memorial Hospital For Cancer And Allied Diseases | Células para imunoterapia melhorada e uso das mesmas |
CA3149897A1 (fr) | 2019-09-03 | 2021-03-11 | Daniel Getts | Methodes et compositions d'integration genomique |
KR20220103928A (ko) * | 2019-10-22 | 2022-07-25 | 알로플렉스 바이오테라퓨틱스 | 시험관 내 활성화 및 연쇄 살해 t 세포 집단의 확장 및 종양 세포 사멸 세포로 암 환자의 수동 면역화를 위한 조성물 및 방법 |
US20220401488A1 (en) * | 2019-11-08 | 2022-12-22 | Saad J. Kenderian | Methods and materials for using engineered mesenchymal stem cells to treat inflammatory conditions and degenerative diseases |
CN112941028A (zh) * | 2019-12-09 | 2021-06-11 | 上海细胞治疗集团有限公司 | 纳米抗体基因修饰的间充质干细胞及其制备方法与应用 |
US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
JP2023509999A (ja) * | 2020-01-14 | 2023-03-10 | アダプティミューン・リミテッド | がんまたは腫瘍の治療の方法 |
IL295896A (en) * | 2020-02-26 | 2022-10-01 | Biograph 55 Inc | c19 c38 bispecific antibodies |
CN115335087A (zh) * | 2020-04-01 | 2022-11-11 | 南京传奇生物科技有限公司 | 用于减少同种异体细胞疗法中的移植物排斥的组合物和方法 |
KR20230042698A (ko) * | 2020-06-29 | 2023-03-29 | 메모리얼 슬로안 케터링 캔서 센터 | C825 발현 면역 세포 및 이의 진단 용도 |
EP4196490A1 (fr) * | 2020-10-27 | 2023-06-21 | PACT Pharma, Inc. | Compositions et méthodes pour le traitement du cancer au moyen d'une thérapie cellulaire nouvelle génération à base de lymphocytes t modifiés |
MX2023005201A (es) | 2020-11-04 | 2023-06-28 | Myeloid Therapeutics Inc | Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas. |
WO2022272102A2 (fr) * | 2021-06-24 | 2022-12-29 | Georgia Tech Research Corporation | Méthodes et compositions pour le contrôle à distance de thérapies de lymphocytes t par ciblage thermique |
CN113789299B (zh) * | 2021-10-18 | 2023-03-24 | 新鲁细胞生物科技(海南)有限公司 | 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法 |
WO2024077270A1 (fr) * | 2022-10-07 | 2024-04-11 | Senti Biosciences, Inc. | Récepteurs chimériques armés et leurs méthodes d'utilisation |
WO2024107410A1 (fr) * | 2022-11-14 | 2024-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Sélection de cd39 pour cytotoxicité de lymphocytes t régulateurs génétiquement modifiés |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013040371A2 (fr) * | 2011-09-16 | 2013-03-21 | Baylor College Of Medicine | Ciblage du microenvironnement tumoral au moyen de cellules nkt modifiées |
WO2014130657A1 (fr) * | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Traitement du cancer au moyen d'un récepteur d'antigènes chimériques anti-egfrviii humanisés |
WO2015142661A1 (fr) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Récepteur d'antigène chimèrique régulable |
WO2015188119A1 (fr) * | 2014-06-06 | 2015-12-10 | Bluebird Bio, Inc. | Compositions de lymphocytes t améliorées |
WO2016014530A1 (fr) * | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car |
WO2016210129A1 (fr) * | 2015-06-23 | 2016-12-29 | Memorial Sloan-Kettering Cancer Center | Nouveaux agents de modulation immunitaire pd -1 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5215964A (en) * | 1991-06-03 | 1993-06-01 | Immunobiology Research Institute, Inc. | Peptides useful in regulating the immune and nervous systems |
WO1999023216A2 (fr) * | 1997-11-03 | 1999-05-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci |
ES2367430T3 (es) * | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
BRPI0707106B1 (pt) * | 2006-01-13 | 2022-06-07 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Polinucleotídeo interleucina-15, vetor de expressão, e, composição farmacêutica |
MX2015011095A (es) * | 2013-02-26 | 2016-03-11 | Sloan Kettering Inst Cancer | Composiciones y metodos para inmunoterapia. |
-
2016
- 2016-06-30 WO PCT/CN2016/087855 patent/WO2017133175A1/fr active Application Filing
-
2017
- 2017-01-26 EP EP17746953.3A patent/EP3411079A4/fr not_active Withdrawn
- 2017-01-26 WO PCT/CN2017/072723 patent/WO2017133633A1/fr active Application Filing
- 2017-01-26 CN CN201780010175.2A patent/CN108883202A/zh active Pending
- 2017-01-26 US US16/075,220 patent/US20190038671A1/en not_active Abandoned
- 2017-01-26 JP JP2018560705A patent/JP2019504892A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013040371A2 (fr) * | 2011-09-16 | 2013-03-21 | Baylor College Of Medicine | Ciblage du microenvironnement tumoral au moyen de cellules nkt modifiées |
WO2014130657A1 (fr) * | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Traitement du cancer au moyen d'un récepteur d'antigènes chimériques anti-egfrviii humanisés |
WO2015142661A1 (fr) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Récepteur d'antigène chimèrique régulable |
WO2015188119A1 (fr) * | 2014-06-06 | 2015-12-10 | Bluebird Bio, Inc. | Compositions de lymphocytes t améliorées |
WO2016014530A1 (fr) * | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car |
WO2016210129A1 (fr) * | 2015-06-23 | 2016-12-29 | Memorial Sloan-Kettering Cancer Center | Nouveaux agents de modulation immunitaire pd -1 |
Non-Patent Citations (1)
Title |
---|
See also references of WO2017133633A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017133175A1 (fr) | 2017-08-10 |
EP3411079A1 (fr) | 2018-12-12 |
WO2017133633A1 (fr) | 2017-08-10 |
US20190038671A1 (en) | 2019-02-07 |
JP2019504892A (ja) | 2019-02-21 |
CN108883202A (zh) | 2018-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3411079A4 (fr) | Cellules mammifères génétiquement modifiées pour thérapie anticancéreuse | |
HK1255161A1 (zh) | 用於過繼性細胞治療的工程細胞 | |
EP3532079A4 (fr) | Procédés viraux de thérapie par lymphocytes t | |
EP3364969A4 (fr) | Méthodes de préparation de lymphocytes t pour traitement par lymphocytes t | |
EP3307876A4 (fr) | Cellules nk-92 modifiées pour traiter le cancer | |
IL250072A0 (en) | Transgenic cells for stress cell therapy | |
EP3092006A4 (fr) | Thérapie ciblée pour le cancer du poumon à petites cellules | |
EP3268465A4 (fr) | Méthodes de traitement du cancer au moyen de cellules t activées | |
EP3370743A4 (fr) | Méthodes de préparation de lymphocytes pour thérapie par transfert adoptif de lymphocytes t | |
EP3302507A4 (fr) | Procédés de diagnostic pour thérapie par lymphocytes t | |
EP3283611A4 (fr) | Système d'enrichissement de cellules cancéreuses | |
EP3250695A4 (fr) | Cellules immunitaires universelles pour l'immunothérapie anticancéreuse | |
EP3666887A4 (fr) | Méthode d'activation des cellules t pour le traitement du cancer | |
EP3545001A4 (fr) | Vaccin à cellules tumorales allogéniques | |
EP3207377A4 (fr) | Diagnostic de cellules tumorales circulantes pour une thérapie ciblée à pd-l1 | |
EP3171897A4 (fr) | Implant composite biopolymère-nanoparticules pour le pistage des cellules tumorales | |
EP3467091A4 (fr) | Système de traitement de cellules | |
EP3413927A4 (fr) | Cancérothérapie | |
EP3091999A4 (fr) | Compositions cellulaires améliorées et procédés pour la thérapie du cancer | |
EP3298448A4 (fr) | Microscope optogénétique | |
EP3334460A4 (fr) | Biomatériaux pour une thérapie d'association radiothérapie-chimiothérapie contre le cancer | |
EP3400013A4 (fr) | Anticorps spécifiques pour la cadhérine-17 et cellules cytotoxiques pour le traitement du cancer | |
EP3802802A4 (fr) | Thérapie cellulaire | |
EP3213752A4 (fr) | Composition pour un traitement visant les cellules souches cancéreuses | |
EP3132802A4 (fr) | Agent thérapeutique pour un cancer solide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180903 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190926 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/22 20060101ALI20190920BHEP Ipc: A61P 35/00 20060101ALI20190920BHEP Ipc: A61K 48/00 20060101AFI20190920BHEP Ipc: C12N 5/16 20060101ALI20190920BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40000527 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200827 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20210112 |